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The T helper 9 (Th9) cell transcriptional network is formed by an equilibrium of signals
induced by cytokines and antigen presentation. Here we show that, within this network,
two interferon regulatory factors (IRF), IRF1 and IRF4, display opposing effects on Th9
differentiation. IRF4 dose-dependently promotes, whereas IRF1 inhibits, IL-9 production.
Likewise, IRF1 inhibits IL-9 production by human Th9 cells. IRF1 counteracts IRF4-driven Il9
promoter activity, and IRF1 and IRF4 have opposing function on activating histone
modiﬁcations, thus modulating RNA polymerase II recruitment. IRF1 occupancy correlates
with decreased IRF4 abundance, suggesting an IRF1-IRF4-binding competition at the Il9 locus.
Furthermore, IRF1 shapes Th9 cells with an interferon/Th1 gene signature. Consistently,
IRF1 restricts the IL-9-dependent pathogenicity of Th9 cells in a mouse model of allergic
asthma. Thus our study reveals that the molecular ratio between IRF4 and IRF1 balances
Th9 fate, thus providing new possibilities for manipulation of Th9 differentiation.
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T
he generation of T helper (Th) subsets enables speciﬁc
targeting of pathogens. Signals triggered by antigen
recognition, costimulation and cytokines lead to the
activation and differentiation of naive T cells by inducing a
network of interacting transcription factors that guide their
differentiation into distinct Th subsets. The expression of
hallmark cytokines characterizes each subset and outlines their
speciﬁc effector properties1. Interferon (IFN)-g-producing Th1
cells express the master regulator T-bet and promote clearance of
intracellular pathogens, whereas Th2 cells secreting interleukin
(IL)-4, IL-5 and IL-13 are characterized by the master
transcription factor GATA3 and contribute to immunity against
helminths. IL-17-, IL-21- and IL-22-producing Th17 cells depend
on the lineage-speciﬁc transcription factor retinoic acid–related
orphan receptor-gt (RORgt) and have a fundamental function in
protection from extracellular bacterial and fungal infections.
However, Th cell subsets can exert both beneﬁcial and
detrimental effects; Th1 and Th17 cells have been implicated in
autoimmune tissue inﬂammation, and Th2 cells can contribute
to allergy and asthma1–5. Furthermore, although Th9 cells
(characterized by IL-9 production) are involved in immunity
against helminths6 and antitumour responses7–9, these cells also
contribute to immunopathologies, including asthma10–12, atopic
dermatitis13, autoimmunity14 and colitis15. Hence, unraveling
the transcriptional network that regulates Th9 differentiation is
pivotal for understanding protective as well as pathogenic effects
in atopic and autoimmune diseases.
Th9 cell differentiation is dictated by the cytokine transforming
growth factor-b (TGF-b) in combination with IL-4 (refs 6,16),
cytokines that shape the transcriptional Th9 network in concert
with T-cell receptor (TCR)-induced and IL-2-induced signals.
TGF-b-induced PU.1 binds directly to the Il9 promoter and
probably enhances IL-9 production by modulating permissive
histone acetylation at the Il9 locus10,17. CD4þ T cells deﬁcient in
IL-2 do not produce IL-9 and this defect can be reversed by the
addition of exogenous IL-2, which induces signal transducer and
activator of transcription factor 5 (STAT5)-mediated activation
of the Il9 promoter18–20. IL-4 via STAT6 signalling positively
regulates Th9 differentiation by enhancing Il9 promoter
activity21,22 and by upregulating the transcription factor
GATA3, which promotes Th9 fate16,23. Furthermore STAT6
signalling counteracts the IL-9-suppressing transcription factor
Foxp3 (refs 16,24,25). Importantly, IL-2/STAT5 (ref. 26) and
IL-4/STAT6 (ref. 22) as well as TCR signalling27 promote the
expression of interferon regulatory factor 4 (IRF4), which is
essential for Th9 differentiation11.
The IRF family of transcription factors consists of nine
members; each IRF comprises of a well-conserved DNA-binding
domain (DBD), but most IRFs also contain an IRF association
domain, which is responsible for homologous as well as
heterologous interactions27. Compared to other members of the
IRF family, IRF4 has lower afﬁnity for the consensus binding
motif termed interferon-stimulated response elements (ISRE).
IRF4 rather binds cooperatively with other transcription
factors to composite regulatory elements28,29. In conjunction
with the activator protein 1 (AP-1) family member BATF,
IRF4 binds preferentially to AP-1-IRF4 composite element
(AICE) motifs30–33, whereas complexes of IRF4 and proteins
from the ETS family, including PU.1, interact at ETS-IRF
composite element (EICE) motifs34,35. IRF4 and BATF are
crucial factors for Th9 differentiation12 and consequently,
IRF4- or BATF-deﬁcient mice are resistant to Th9-dependent
allergic airway disease11,12. The importance of IRF4 is further
demonstrated in T cells deﬁcient in the tyrosine kinase Itk, which
is an important component of TCR-mediated signalling. Altered
TCR signalling in these cells leads to IL-9 inhibition due to
attenuated IRF4 expression, which can be rescued by
IL-2/STAT5-mediated IRF4 induction26. Hence, IRF4 has not
only a fundamental role in the differentiation of Th9 but is also
known to control Th2, Th17, T follicular helper and T regulatory
cell speciﬁcation27.
The ﬁrst member of the IRF family, IRF1, favours
Th1 differentiation in an intrinsic manner by enhancing the
expression of IL-12 receptor b1 subunit36 and also in a
T-cell-extrinsic manner by increasing IL-12 production by
antigen-presenting cells37,38. Conversely, IRF1 suppresses the
production of IL-4, IL-5 and IL-13 in Th2 cells39,40. Thus IRF1
balances Th1 versus Th2 differentiation, and dysregulated IRF1
consistently associates with atopy41 and allergic asthma42,
immunopathologies linked to both Th2 and Th9 cells. IRF1 is
expressed at low levels by most cell types and is induced by
various stimuli, including IL-1, lipoploysaccharide, tumour
necrosis factor and IFNs. In Th2 cells, IFN-g stimulation in
combination with TCR signalling, strongly upregulates IRF1
expression leading to its increased binding to ISRE, thus
inhibiting IL-4 production39. Likewise, IFN-g is known to
inhibit IL-9 production via STAT1 (refs 19,43); however, the
exact cellular mediators downstream of STAT1 are not known44.
Three conserved non-coding sequences (CNS) have been
described for the Il9 locus, CNS0, 1 and 2, whereby the
promoter (CNS1) harbours important transcription factor-
binding sites for Il9 regulation45. Among them, several ISRE
motifs can be found and IRF1 as well as IRF4 bind to the Il9
promoter9,11. Considering these ﬁndings and that both IRF1 and
IRF4 can be upregulated in Th9 cells9,11, we speculated on a yet
unknown interference between these two IRFs during Th9
differentiation.
Here we provide evidence that IFN-g-mediated upregulation
of IRF1 limits IL-9 production in human and mouse Th9 cells.
IRF1 suppresses IRF4-driven IL-9 production and counteracts
IRF4-driven Il9 promoter transactivation. Decreased IRF4
abundance correlates with IRF1 binding at the Il9 locus,
suggesting possible competitive binding among these factors.
Furthermore, IRF4 and IRF1 display opposing activities on the
chromatin state, thus possibly contributing to differential
RNA polymerase II recruitment to Il9. Genome-wide analyses
reveal that IRF1 imprints Th9 cells with a Th1/IFN-associated
gene signature, while suppressing Th9 genes. Consistently,
IRF1 suppresses Th9 cell-mediated allergic airway disease in an
IL-9-dependent manner. Collectively, our data reveal direct
opposing activities between IRF members on Th9 differentiation.
Results
IRF1 suppresses IRF4-dependent IL-9 production in Th9 cells.
To examine whether there is a mutual regulation between IRF1
and IRF4 expression in Th9 cells, we determined IRF1 and IRF4
protein levels in the presence or absence of IFN-g, which is a
known IRF1 inducer46. As expected, IRF1 was strongly
upregulated by IFN-g in Th9 cells (Fig. 1a,b) in a STAT1-
dependent manner (Supplementary Fig. 1a,b). The upregulation
of IRF1 by IFN-g did not affect the levels of co-expressed
IRF4 and vice versa (Fig. 1a,b). Furthermore, neither the
expression of several transcription factors involved in Th9
differentiation10,12,16,18,21–25 including PU.1 (encoded by Spi1),
BATF, GATA-3 and T-bet nor the phosphorylation levels of
STAT3 and STAT5 were signiﬁcantly affected by IRF1-deﬁciency
(Supplementary Fig. 1c–g). The expression of Foxp3, which
represses Th9 differentiation16,22,25, was slightly upregulated
in Irf1 / as compared to wild-type (WT) Th9 cells
(Supplementary Fig. 1h).
Although IRF1 did not interfere with the levels of IRF4 and
other transcription factors contributing to Th9 differentiation,
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it was still conceivable that it affects IL-9 expression in Th9
cells by other mechanisms. To test this possibility, we sorted
naive CD62LþCD44CD4þ WT, Irf1 / and Stat1 / cells,
cultured them under Th9-skewing conditions in the presence
or absence of IFN-g and analysed IL-9 production. IFN-g
suppressed the proportion of IL-9-producing WT cells, which is
consistent with previous ﬁndings19, while it rather supported
the generation of IL-9-producing cells in the absence of IRF1
or STAT1 (Fig. 1c), indicating that IFN-g suppressed IL-9
production in Th9 cells via STAT1-induced IRF1. Thus,
in contrast to the known positive regulation of IL-9 by IRF42,
IRF1 displayed an opposite effect when induced by IFN-g,
implying that there might be an interference between these two
transcription factors during IL-9 regulation in Th9 cells.
To proof this hypothesis, we co-transfected Irf4 / Th9 cells,
which produce low amounts of IL-9, with a retroviral vector
encoding IRF4 tagged with green ﬂuorescent protein (GFP)
(IRF4-GFP-RV) and with a vector encoding Thy1.1-tagged IRF1
(IRF1-Thy1.1-RV) or with corresponding control empty vectors
(Control-Thy1.1-RV, Control-GFP-RV). Then the cells were
analysed for IL-9, IRF1 and IRF4 expression. While cells that
were transduced with neither virus displayed low IL-9 positivity
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Figure 1 | IRF1 limits IRF4-driven IL-9 production dose-dependently. (a–c) Naive CD44CD62LþCD4þ T cells were isolated from WT, Irf4 / ,
Irf1 / or Stat1 / mice and then treated under Th9 (TGF-b and IL-4) or Th0 (without skewing cytokines) conditions with/without IFN-g as indicated.
(a,b) After resting and reculture under Th9 conditions for 2 days, intracellular ﬂow cytometric analysis for IRF1 and IRF4 were performed. Bars give
geometric mean of ﬂuorescence intensity (MFI). (c) Cells were restimulated and then IL-9 and IFN-g production was detected by ﬂow cytometry, bars to
the right give mean of IL-9þ T cells. (d,e) Irf4 / CD4þ T cells were isolated, activated under Th0 condition overnight and then spin-infected with
retroviruses as indicated: IRF4-GFP-RV, control-Thy1.1-RV, and IRF1-Thy1.1-RV. Thereafter, cells were cultured under Th9 conditions for 2 days, rested for 3
days and recultured under Th9 conditions for additional 2 days. Four subsets (I–IV) were selected for analysis of IL-9 production. Bars to the right show fold
induction of IL-9þ T cells relative to GFPThy.1.1 cells (subset I). (e) Six subsets (a through f) expressing increasing levels of GFP and Thy1.1 were
selected for analysis of IL-9 production (left panel). Dot plot to the left is representative for four independent experiments. Graph to the right shows fold
induction of IL-9þ T cells relative to GFPThy1.1 cells (subset a) combined from four independent experiments. Histogram and contour-plots are
representative of two (a,b), three (c) or four (d,e) independent experiments. Bars show mean±s.d. from combined two (a,b), three (c) or four (d,e)
experiments. *Po0.05, **Po0.005, ***Po0.001 (two-tailed Student’s t-test).
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms15366 ARTICLE
NATURE COMMUNICATIONS | 8:15366 |DOI: 10.1038/ncomms15366 | www.nature.com/naturecommunications 3
(Thy1.1GFP ), as expected, a substantial proportion of the
cells transduced with IRF4-GFP-RV (Thy1.1GFPþ ) highly
produced IL-9 (Fig. 1d). This effect was reversed in cells that had
been co-infected with IRF1-Thy1.1-RV (Thy1.1þGFPþ , Fig. 1d,
bottom panel). The suppression was speciﬁc for IRF1 because
the Control-Thy1.1-RV did not diminish IRF4-driven IL-9
production signiﬁcantly (Thy1.1þGFPþ , Fig. 1d, upper panel).
Importantly, IRF1-mediated inhibition of IL-9 production was
dose-dependent and restricted to IRF4-promoted IL-9 production
(Fig. 1e). The high expression of GFP and Thy1.1 correlated
with high IRF1 and IRF4 expression in Irf4 / Th9 cells
transduced with IRF4-GFP-RV and IRF1-Thy1.1-RV, respectively
(Supplementary Fig. 2a). Of note, the relative intensities of
GFP and Thy1.1 tags representing the relative expression of
IRF1 and IRF4 correlated with IRF4 and IRF1 protein levels
(Supplementary Fig. 2b,c). Thus these results imply that IRF1
suppresses IRF4-driven IL-9 production in a quantitative manner.
IRF1 and IRF4 control the Il9 locus. Since IRF4 and most
transcription factors related to Il9 locus regulation exert their
function through direct binding to the Il9 promoter45, we
analysed IRF4 and IRF1 binding and their functional interference
at the Il9 promoter. For this, we performed reporter assays in
non-polarized CD4þ T cells transfected with an Il9 promoter-
luciferase construct (pGL3-Il9) and IRF1- and/or IRF4-encoding
plasmids. Co-transfection of the Il9 promoter-luciferase construct
with IRF4 resulted in transactivation (Fig. 2a), as previously
described11. Consistent with the repressive activity of IRF1 on
IRF4-mediated IL-9 production, the co-transfection of IRF1
suppressed IRF4-driven Il9 promoter activity in non-polarized
CD4þ T cells (Fig. 2a). The inhibitory IRF1 effect was dose-
dependent and relied on the DBD (Fig. 2b,c), suggesting that
IRF1 might directly interfere with the transactivating effects of
IRF4 at the Il9 promoter. We further conﬁrmed the role of IRF1
DBD on IL-9 production in Th9 cells using overexpression of
retroviral vectors encoding IRF1DDBD (IRF1DDBD-GFP-RV),
IRF1 (IRF1-GFP-RV) or control vector (Control-GFP-RV)
(Supplementary Fig. 3a,b).
In order to evaluate the underlying molecular mechanisms
of IRF1- and IRF4-dependent Il9 regulation, we performed
chromatin immunoprecipitation (ChIP) with IRF4- and
IRF1-speciﬁc antibodies in Th9 cells followed by sequencing
(ChIP-Seq) as described47. To determine the permissive histone
marks of regions bound by IRF1 or IRF4, we included ChIP-Seq
analyses for acetylated histone H3 at Lys27 (H3K27-Ac), which
is found in active regulatory regions48. We identiﬁed high-
conﬁdence genome-wide binding regions for IRF4; interestingly
approximately 60% of these IRF4 peaks were lost upon IFN-g
signalling (15,174 of the 24,457 IRF4 peaks lost, Fig. 2d).
We analysed the occurrence of AICE, EICE and ISRE
motifs coinciding with IRF1 and IRF4 peaks. As previously
described30–33, IRF4 binding highly associated with AICE motif
prevalence, whereas ISRE as well as EICE motifs were rather
bound with lower frequency by IRF4 in Th9 cells (Fig. 2e). In
contrast, IRF1 peaks highly correlated with ISRE occurrence in
Th9 cells upon IFN-g treatment, as expected (Fig. 2e). Consistent
with motif analyses, IRF1 and IRF4 binding did overlap in some
regions (Supplementary Fig. 3c).
Next we focused on the Il9 locus and determined IRF4-binding
sites within CNS1. Considering IRF4 preferential genome-wide
binding to AICE, we surprisingly found that two mutations
(termed M1 and M3) in ISRE motifs (in the region termed
IRF-CNS1) abrogated IRF4-promoted Il9 promoter activity in
luciferase assays indicating that these ISRE are crucial for positive
regulation of Il9 promoter activity by IRF4 (Fig. 2f). Interestingly,
we detected higher IRF4-binding density in Th9 cells than in Th9
cells treated with IFN-g mainly at CNS1 and CNS0 and (to a
smaller extent) also at CNS2 of the Il9 locus (Fig. 2g,h). In
contrast, IRF1 binding to the Il9 locus was induced by treatment
of Th9 cells with IFN-g (Supplementary Fig. 3d). IRF1 bound at
CNS1 as previously described9 as well as at CNS0 and CNS2
(Fig. 2g). Thus decreased IRF4 abundance correlated with the
appearance of IRF1 peaks at the same regions located in the Il9
locus and this was accompanied by slightly decreased H3K27-Ac
occupancy (Fig. 2g). These results suggest that IRF1 might impair
IL-9 production by competing with IRF4 binding at ISRE in
the Il9 locus.
Opposite regulation of histone marks by IRF1 and IRF4.
For efﬁcient transcription, the locus must be held in an open
conformation, which can be monitored by characteristic histone
modiﬁcations, for example, acetylation49. In Th9 cells, the
acetylation of histones H3 and H4 at Il9 CNS is associated with
enhanced Il9 transcription10,25. Reciprocal binding of IRF1 and
IRF4 to the Il9 locus accompanied by differential regulation of
IL-9 production suggested that these transcription factors
might alter epigenetic modiﬁcations. ChIP-Seq analysis (Fig. 2g)
supported this hypothesis to some extent. To closer approach
this issue, we performed ChIP followed by quantitative real
time-PCR (qRT-PCR) analysis at Il9 CNS for total acetylation of
histone H4 (H4-Ac). We found less H4-Ac at the CNS0 and
CNS2 in Irf4 / Th9 cells as compared to WT Th9 cells
(Fig. 3a) and this correlated with decreased RNA polymerase II
(pol II) abundance at the Il9 gene (Fig. 3b), suggesting that the
positive regulation of the acetylation status by IRF4 supports Il9
transcription. In contrast, IFN-g treatment suppressed H4-Ac
at Il9 CNS in WT but not in Irf1 / Th9 cells (Fig. 3c,
Supplementary Fig. 4a). This was accompanied by a decreased pol
II recruitment to the Il9 gene upon IFN-g treatment in WT Th9
cells, and this effect was reversed by IRF1 deﬁciency (Fig. 3d).
This implies that negative regulation of histone acetylation state
by IRF1 may contribute to the restricted Il9 transcription. In
non-stimulated WT and Irf1 / CD4þ T cells, no differences in
H4-Ac at Il9 CNS were detectable, indicating that the described
differences in the H4-Ac status were not caused by developmental
alterations (Supplementary Fig. 4b). To analyse whether
IRF1 suppresses histone acetylation by recruitment of histone
deacetylases (HDAC), we applied the HDAC inhibitor
trichostatin A during Th9 polarization in the presence or
absence of IFN-g. Under both conditions, we observed similar
increase in IL-9 production by Th9 cells upon addition of the
inhibitor (Supplementary Fig. 4c). This indicates that IRF1
suppresses chromatin accessibility independently of HDAC
recruitment to the Il9 locus. These data reveal an opposite
regulation of histone acetylation at Il9 CNS by IRF4 and IRF1.
IRF1 imprints Th9 cells with IFN-c-/Th1-associated signature.
On a genome-wide level, IFN-g signalling caused both
hypoacetylation and hyperacetylation on loci in Th9 cells,
indicating a differential regulation of regulatory regions (Fig. 4a).
To understand the extent to which IRF1 contributes to
transcriptional programming of Th9 cells on a global level, we
performed RNA sequencing (RNA-Seq) from WT or Irf1 /
Th9 cells treated with IFN-g. There were 735 signiﬁcantly
downregulated, while 604 signiﬁcantly upregulated transcripts
(Po0.01) in Irf1 / relative to WT Th9 cells (Fig. 4b),
indicating that IRF1 signalling negatively and positively regulates
genes downstream of IFN-g. Gene-set enrichment analysis
(GSEA) using Molecular Signatures Database (MSigDB, Broad
Institute) as well as published gene expression signatures12
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revealed that positively regulated genes by IRF1 signalling (those
upregulated in WT as compared to Irf1 / Th9 cells) were
enriched for IFN-g response genes and Th1 signature-associated
genes (Fig. 4c,d, Supplementary Fig. 5a,b). In contrast, the
negatively regulated genes (those downregulated in WT cells
as compared to Irf1 / Th9 cells) were enriched for genes
associated with a Th9 signature (Fig. 4e, Supplementary Fig. 5c).
Hence, IFN-g-IRF1 signalling promotes a transcriptional shift of
Th9 cells towards an IFN-g/Th1 signature. This was further
conﬁrmed by functional enrichment analysis on sets of genes
derived from IRF1 promoter-binding proﬁles. A majority of
pathways linked to the IFN/Th1 signature overlapped between
GSEA and ChIP-Seq-based gene ontology (GO) enrichment
analysis of IRF1 targets, including viral response pathways as well
as IL-12- and IFN-associated pathways (Supplementary Data 1).
Among the genes positively regulated by IRF1 signalling and
directly bound by IRF1, we found the already known targets,
guanylate-binding protein 2 (Gbp2) and Gbp5 (refs 50,51), which
contribute to clearance of infection as well as Th1-associated
genes, including Il12rb1 (refs 1,36; Fig. 4f). Collectively, the data
suggest that IRF1 can act as a direct activator of IFN/Th1
pathways, implying that IRF1 signalling modulates the
transcriptional fate of Th9 cells by enriching IFN-g/Th1-
associated gene signatures, while limiting Th9-associated genes.
IRF1 limits allergic airway inﬂammation IL-9 dependently.
As IRF1 single-nucleotide polymorphisms associate with child-
hood allergic asthma42 and IL-9 production is postulated to be an
initial event promoting allergy52, we analysed the role of IRF1 in a
murine model of allergic asthma. However, allergy studies directly
in Irf1 / mice will not be informative due to defects in antigen-
presenting cells37,46 in addition to T-cell-intrinsic alterations.
To circumvent this difﬁculty, we polarized WT and Irf1 /
OTII cells, carrying a transgenic TCR speciﬁc for chicken
ovalbumin (OVA), under Th9 conditions in the presence of
IFN-g. Thereafter, the cells were injected into mice lacking T and
B cells (Rag2 / ), which were subsequently challenged with
OVA to provoke asthma symptoms (Supplementary Fig. 6a).
Irf1 / compared to WT OTII Th9 cells caused signiﬁcantly
increased eosinophil numbers in broncho-alveolar lavage (BAL)
ﬂuid, while macrophage numbers were decreased (Fig. 5a).
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NATURE COMMUNICATIONS | DOI: 10.1038/ncomms15366 ARTICLE
NATURE COMMUNICATIONS | 8:15366 |DOI: 10.1038/ncomms15366 | www.nature.com/naturecommunications 5
*CNS0 CNS1 CNS2
1.0
1.5
0.5
0.0
2.0
4
6
2
0
8
CNS0
8
4
6
2
0
10
CNS2
WT Th9
Irf4–/–Th9 
WT Th9
Irf1–/–Th9 
WT Th9
Irf1–/–Th9 
WT Th9
Irf4–/–Th9 
*
***
a
c d
b Il9 gene
**
0.25
0.05
0.10
0.15
0.00
0.20
0.5
0.0
1.0
1.5
Rpl32
NS
H
4-
Ac
 (fo
ld)
H
4-
Ac
 (%
 in
pu
t)
Po
l I
I (%
 in
pu
t)
0.5
1.0
0
1.5
CNS1
NS
Po
l I
I (%
 in
pu
t)
Il9 gene
2
3
1
0
4
+– +IFN-γ
Rpl32
*
NS
2
3
1
0
4
+– +IFN-γ +– + +– +
1
2
0
3
2.0
1.0
1.5
0.5
0.0
2.5
+– +
*
**
*
***
*
NS
NS
NS
Figure 3 | Opposite effects of IRF1 and IRF4 on histone acetylation at Il9 locus. (a–d) Puriﬁed WTand (a,b) Irf4 / or (c,d) Irf1 / CD4þ Tcells were
cultured under Th9 conditions with or without IFN-g. (a,c) ChIP analysis of histone H4 acetylation (Ac) at CNS of the Il9 gene. (c) Bars show fold induction
of H4-Ac relative to WT Th9 cells treated with IFN-g. (b,d) ChIP analysis for RNA polymerase II (pol II) occupancy at Il9 and Rpl32 genes. (a–d) The same
chromatin was used for control ChIP experiments with control IgG. Precipitated DNA is presented relative to input (% input). Values for nonspeciﬁc binding
(as determined by using control IgG) were subtracted. (a–d) Data are shown as mean±s.d. of combined results from two independent experiments
(triplicates to quintuplets in qRT-PCR). The experiments were repeated (b) three or (d) ﬁve times with consistent results. *Po0.05, **Po0.005,
***Po0.001 (two-tailed Student’s t-test).
[0 – 20]
IRF1
IFN-γ response-associated genes 
FDR = 0.07
FWER P value = 0.048
Rank in ordered data set
2,500 5,000 7,500
Zero cross at 10,246 Zero cross at 10,246
10,000 12,500 15,000 17,500 20,000 22,5000
a
b
f
c d e
wt Th9+IFN-γ
(positively correlated)
Irf1–/– Th9+IFN-γ
(negatively correlated)
Th9-associated genesTh1-associated genes 
FDR = 0.10
FWER P value < 0.01
Th9+IFN-γ
wt Irf1–/–
1.5
0.0
–1.5
0.0
0.1
0.2
0.3
0.4
0.5
0.6
–2.5
0.0
2.5
5.0
Er
ic
hm
en
t s
co
re
Er
ic
hm
en
t s
co
re
Er
ic
hm
en
t s
co
re
R
an
ke
d 
lis
t m
et
ric
R
an
ke
d 
lis
t m
et
ric
R
an
ke
d 
lis
t m
et
ric
 
 
–0.1
0.0
0.1
0.2
0.3
 –2.5
0.0
2.5
5.0
2,500 5,000 7,500 10,000 12,500 15,000 17,500 20,000 22,5000
Rank in ordered data set
 
 
FDR = 0.10
FWER P value < 0.01
Rank in ordered data set
2,500 5,000 7,500 10,000 12,500 15,000 17,500 20,000 22,5000
–0.1
0.0
0.2
0.3
–5.0
–2.5
0.0
2.5
0.4
0.1
[0 – 7.00]
[0 – 7.00]
5 kb [0 – 40]
[0 - 7.00]
[0 – 7.00]
5 kb
Gbp2Gbp2b Il12rb1
[0 – 30]
[0 – 3.00]
[0 – 3.00]
5 kb
Gbp5 Gbp7
H3K27-Ac
H3K27-Ac
+IFN-γ
+IFN-γ
Th
9
–
16,254 29,821 6,756
H3K27-Ac
Th9
H3K27-Ac
Th9+IFN-γ
wt Th9+IFN-γ
(positively correlated)
wt Th9+IFN-γ
(negatively correlated)Irf1
–/–
 Th9+IFN-γ
(negatively correlated)
Irf1–/– Th9+IFN-γ
(positively correlated)
Zero cross at 11,321
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This was accompanied by increased presence of mucus-producing
cells in recipients of Irf1 / compared to WT OTII Th9 cells
(Fig. 5b). Additionally, OVA-stimulated lung cells isolated from
recipients of Irf1 / compared to WT OTII Th9 cells produced
more IL-9 and IL-13 but less IFN-g (Fig. 5c–e), revealing that
Irf1 / Th9 cells retain their pro-allergic phenotype in vivo as
compared to WT Th9 cells. The pro-allergic function of Irf1 /
Th9 cells was ameliorated by treatment with IL-9-neutralizing
antibodies as determined by decrease in eosinophilia, in the
numbers of mucus-producing cells and in inﬂammation
(Fig. 5f–h, Supplementary Fig. 6b,c). Accordingly, the amounts
of secreted IL-9 and IL-13 (which is regulated by IL-9 in
asthma53) were strongly diminished by IL-9 neutralization
(Supplementary Fig. 6d,e). Thus IFN-g/IRF1 signalling restricts
Th9-mediated airway allergy in an IL-9-dependent manner while
enhancing IFN-g production in Th9 cells, indicating that IRF1
constrains allergic airway disease by skewing Th9 cells towards a
‘low-allergic’ IFN/Th9 phenotype.
IRF1 suppresses IL-9 production in human Th9 cells. Finally,
we investigated whether IRF1 also regulates IL-9 production in
human Th9 cells. For this, we isolated naive CD4þCD25
CD45RAþCD45RO T cells from peripheral blood mono-
nuclear cells (PBMCs) of healthy human subjects and activated
them in the absence of skewing cytokines (Th0 conditions) or in
the presence of TGF-b plus IL-4 (Th9 conditions) with or without
addition of IFN-g. As already reported11,54, Th9 conditions
induced IL-9 production by CD4þ T cells, whereas the addition
of IFN-g counteracted this effect and simultaneously upregulated
IFN-g (Fig. 6a). This was conﬁrmed by qRT-PCR and detection
of IL-9 in supernatants of cultured cells (Fig. 6b,c). Similar to
murine Th9 cells (Supplementary Fig. 1a), the addition of IFN-g
caused increased phosphorylation of STAT1 also in human Th9
cells (Fig. 6d) and this was accompanied by upregulation of IRF1,
which was co-expressed with IRF4 (Fig. 6e). Knockdown of IRF1
expression by siRNA (Fig. 2f) abolished IFN-g-mediated
suppression of IL9 mRNA expression and IL-9 production in
human Th9 cells (Fig. 6g,h). Thus IFN-g signalling requires IRF1
to suppress IL-9 production in human Th9 cells. This points to
the existence of comparable programmes dictated by the IFN-g-
STAT1-IRF1 pathway suppressing IL-9 production in human and
murine Th9 cells.
Discussion
Th9 cells exert protective as well as pathophysiological immune
functions44; however, the detailed regulation of the Th9
transcriptional network remains incompletely understood. Here
we show that IRF1 limited IL-9 production downstream of IFN-
g/STAT1 signalling in mouse and human Th9 cells. IRF1
repressed IRF4-driven IL-9 production and Il9 promoter
activity in a quantitative manner. Direct IRF1 binding at the Il9
promoter was associated with decreased abundance of IRF4 and
reduced acetylation levels as well as limited RNA polymerase
recruitment at the Il9 locus. These results suggest that the
suppressive function of IRF1 is probably mediated by a direct
binding competition with IRF4 at the Il9 locus, resulting in
opposite regulation of histone acetylation and associated Il9
transcription. IFN-g-induced IRF1 evoked a shift in Th9 cells
towards an IFN/Th1-like signature through direct and indirect
mechanisms. Accordingly, the absence of IRF1 in IFN-g-treated
Th9 cells led to increased IL-9-dependent pathogenicity in AAD,
a mouse model for allergic asthma. Thus the transcriptional
network of Th9 differentiation is shaped by opposing actions of
two IRF family members, IRF1 and IRF4.
Th9 cells contribute to human atopic diseases and accordingly
Th9-related genes associate with asthma development44.
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Figure 5 | The IFN-c/IRF1 pathway restricts Th9-dependent allergic airway inﬂammation. WTor Irf1 / Th9 cells treated with IFN-g were adoptively
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We demonstrated that IFN-g upregulates IRF1 in human Th9
cells and that IRF1 upregulation correlated with decreased
IL-9 production. Furthermore, silencing of IRF1 restored IFN-
g-mediated IL-9 suppression, indicating that IRF1 counteracts
IL-9 production also in human Th9 cells. Indeed, IRF1 single-
nucleotide polymorphisms associate with asthma development
and atopy41,42. In addition, increased levels of IRF4 and IL-9 were
accompanied by diminished IFNG expression in the peripheral
blood of allergic asthmatics55. Given those ﬁndings, one could
speculate that asthmatics might fail to upregulate IRF1 upon
infection-induced IFN-g signalling leading to exacerbated asthma
due to defects in Th9 and Th2 inhibition. However, further work
must be carried out to fully understand the impact of IRF1
signalling on Th9 cells during asthma exacerbations.
To induce asthma pathophysiology in the mouse model,
we performed adoptive transfer experiments of OVA-transgenic
IFN-g-treated WT and Irf1 / Th9 cells into Rag2 / mice
and subsequently challenged the mice with nebulized OVA.
Indeed, the absence of IRF1 resulted in more severe AAD, which
was dependent on IL-9 as shown by neutralization with anti-IL-9
antibody. Besides decreasing IL-9 production, we wondered
whether IRF1 as a transcription factor linked to Th1 differentia-
tion also affects other functionally relevant genes. Therefore, we
made use of genome-wide RNA-Seq to investigate the complex
IRF1-mediated transcriptional interplay in IFN-g-treated Th9
cells. Interestingly, GSEA revealed an IRF1-dependent and
IFN-g-induced shift towards a Th1/IFN-like phenotype, while
suppressing Th9 signature genes. Pathways associated with
infectious and interferon response36,50,51,56, for example, Gbp
and Il2rb1 were directly upregulated, indicating that IRF1
balances Th9 versus Th1-like plasticity by its ability to act
as a transcriptional repressor as well as an activator. Recently,
Ve´gran et al.9 published that IRF1 is a positive regulator of IL-9
and Th9 differentiation when induced by IL-1b and dictates
IL-21-dependent antitumour function in a melanoma model.
However, there are many possible explanations for this
discrepancy to our study. The cytokine signalling triggered by
IL-1b differs greatly from that of IFN-g, therefore it is conceivable
that the cellular milieu contains distinct transcription factors that
might interfere with IRF1 functions. Among these, nuclear
localization of the IL-9-promoting transcription factor nuclear
factor-kB24,25,57 is induced by IL-1b signalling58, which might
alter IRF1 actions. To exclude the inﬂuence of the microbial
environment of the animal facilities, we extended our work to
human Th9 cells where we demonstrated that IRF1 indeed
inhibited IL-9 expression in the context of IFN-g signalling. We
therefore conclude that IFN-g-IRF1 signalling suppresses the Th9
fate in humans and mice.
IRF family members are known to regulate gene expression
positively or negatively in different cell types, including Th cells46.
To carry out these effects, IRFs can interact via the IRF
association domain with family members or with proteins
belonging to other families. For example, IRF1-IRF8
heterodimers mostly act as transcriptional repressors at ISRE,
whereas IRF1, IRF3 and IRF7 form an IFN-b enhanceosome
together with nuclear factor-kB, AP-1 and CBP/p300 to induce
Ifnb expression59. Only few studies describe antagonizing
functions of IRFs at ISRE in gene regulatory. It has been
described that IRF8 represses IRF9 binding to ISRE at
IFN-stimulated gene 15 (ref. 29), while IRF4 counteracted IRF1-
driven tumour necrosis factor-related apoptosis-inducing ligand
promoter activity in a DBD-dependent manner60. Furthermore,
IRF1 opposes IRF4-driven Il17 promoter activity, and conversely,
IRF4 antagonizes IRF1-mediated Il10 promoter activity61.
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Figure 6 | IFN-c/STAT1-induced IRF1 suppresses IL-9 production in human Th9 cells. Naive CD4þCD25CD45RAþCD45RO T cells were isolated
from human PBMCs and cultured under Th0 or Th9 conditions in the presence or absence of human IFN-g as indicated. (a) Intracellular staining for IL-9
and IFN-g after 3 days of culture (bars to the right give mean±s.d. of three independent experiments). (b) Expression of IL9 and IFNG mRNA on day 2 in
Th0 and Th9 cells; results were normalized to 18S and are presented relative to Th0 cells. (c) ELISA of IL-9 in supernatants of Th0 and Th9 cultures after
3 days. (d) Phospho-ﬂow for p-STAT1 in Th9 cells with or without IFN-g treatment, day 2 of culture (values show mean ﬂuoresence intensity).
(e) Intracellular staining for IRF1 and IRF4, day 2 of culture (bars to the right give mean±s.d. of three independent experiments). (f–h) Human naive
CD4þCD25CD45RAþCD45RO T cells were activated under Th0 condition for 16 h, then transfected with scrambled (scr) or IRF1-speciﬁc siRNA
(siIRF1) and then cultured for further 72 h under Th9 conditions with/without IFN-g. (f) Intracellular staining of IRF1 in scr- or siIRF1-transfected cells 24 h
post transfection upon culture under Th9 conditions with IFN-g. (g) Expression of IL9 mRNA in transfected cells at 48 h post transfection; results were
normalized to 18S and are presented relative to Th9 cells treated with scr siRNA and IFN-g. (h) ELISA of IL-9 in supernatants of transfected cells 72 h post
transfection. (a–h) Data are representative of three independent experiments with different donors; *Po0.05, **Po0.005, ***Po0.001 (two-tailed
Student’s t-test).
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In our study, we propose a model in which IRF1 competes with
IRF4 binding at ISRE of the Il9 locus to repress IL-9 expression.
This is substantiated by (i) dose-dependent IRF1-mediated
repression of IRF4-driven Il9 promoter activity, (ii) dose-
dependent suppression of IRF4-triggered IL-9 by overexpressed
IRF1 in Th9 cells and (iii) decreased IRF4 binding in the presence
of IRF1 occupancy at the Il9 locus as shown by ChIP-Seq
analyses. The previously deﬁned IRF4-binding region in the Il9
promoter harbours several ISRE (AANNGAAA) motifs11,45,
which we analysed for IRF4-promoting function. We identiﬁed
two functional IRF4-binding sites at  238/ 226 bp from the
transcription start site on the basis of Il9 promoter activity assays
performed with mutated ISRE. This was surprising because IRF4
peaks associated preferentially with AICE motifs on a genome-
wide scale. As IRF4 (and IRF8), in comparison to other IRF
family members including IRF1, displays lower afﬁnity for
binding to ISRE34, we presume those sites to be competitively
bound by IRF1 leading to opposing regulation of Il9 promoter
activity in Th9 cells.
Transcription factor-induced transactivation is a multilevel
event. After histone methylation-based initiation of active
chromatin formation by pioneering factors, ensuing transcription
factors such as EP300 enable the recruitment of transcriptional
coactivator complexes, which then catalyse local histone acetyla-
tion (H3K27-Ac) required for gene transcription49. Both IRF1
and IRF4 have been shown to affect the histone acetylation status
in immune cells37,62. We indeed detected opposite effects of IRF4
and IRF1 on the histone H4 acetylation status at Il9 regulatory
elements. Thus histone acetylation was decreased in IRF4-
deﬁcient Th9 cells as compared to WT Th9 cells, suggesting
that IRF4 contributes to increased chromatin accessibility at the
Il9 locus. In contrast, IRF1 was crucial for IFN-g-mediated
suppression of permissive histone marks, implying that IRF1
limited the chromatin accessibility at the Il9 CNS. Consistent with
these counteracting activities, the recruitment of RNA pol II,
which is crucial for transcriptional output, was decreased in IRF4-
deﬁcient Th9 cells, while it was increased under IRF1-deﬁciency
as compared to WT cells. This points out that the changes in the
acetylation status may contribute to the opposing regulation of
IL-9 production by IRF4 and IRF1.
The model in which two members of one family competitively
bind at the same cytokine locus has already been demonstrated
for STAT3 and STAT5 in Th17 cells63. In this study, IL-2
signalling mediated its repressing effects via direct DNA binding
of STAT5 at the Il17 locus, which correlated with decreased
STAT3 abundance as well as with decreased H3-Ac. This effect
was mediated by increased binding of a histone deacetylator
adaptor protein termed NCoR2. In our study, the general HDAC
inhibitor trichostatin A was insufﬁcient to oppose IFN-g-
mediated IL-9 repression, suggesting that the IFN-g-IRF1 axis
suppresses IL-9 production in an HDAC-independent manner.
As IRF4 is known to recruit HAT p300 in Th0 and Th17 cells30,
this could also apply for Th9 cells. Along with this idea, one could
speculate that IRF1 counteracts the IRF4-mediated HAT
recruitment or interferes with HAT function. However, more
work has to be done to clarify this issue in detail. A recent study
pointed to competitive binding of IRF1 and IRF4 at the Il17
promoter thereby possibly regulating Th17/Tr1 commitment61.
This is in agreement to our proposed model of IRF1/IRF4
competition as a mechanism to control Th differentiation.
Taken together, our study allows deeper insight into the
function of IRF1 and IRF4 in Th9 cell differentiation and suggests
for the ﬁrst time that IRF1 competes with IRF4 to repress IL-9
production in Th9 cells. Furthermore, we demonstrate that IRF1
regulated gene expression positively on some, whereas negatively
on other loci to shift Th9 cells towards a Th1-like phenotype. The
knowledge of this IRF1-mediated transition of Th9 differentiation
could prove useful for further unravelling Th9- and IFN-g-
associated immune responses during asthma as well as anti-
tumour immunity. Altering the IRF1/IRF4 balance in the
transcriptional network of Th9 cells to either increase or decrease
Th9 responses might display a potential therapeutic approach.
Methods
Mice. C57Bl/6 mice were purchased from The Jackson Laboratory. Irf1 / ,
Irf4 / , Rag2 / and OTII mice expressing a transgenic TCR recognizing
OVA323-339 were bred at the animal facility of the Biomedical Research Center,
University of Marburg. Irf1 / mice were bred with OTII mice to produce
Irf1 / OTII transgenic mice. Stat1 / mice were kindly provided by T. Decker
(Max F. Perutz Laboratories, Department of Genetics, Microbiology and
Immunobiology, University of Vienna, Austria). All mice used in the experiments
were 8–12-week old, at C57Bl/6 background and sex- and age-matched. The
experiments were approved by the local committee (Regierungspra¨sidium Gieen)
and conducted according to the German animal protection law.
Murine CD4þ T cell puriﬁcation and in vitro differentiation. CD4þ T cells
were puriﬁed by negative magnetic cell sorting (CD4þ T cell isolation kit, 130-104-
454, Miltenyi) from the spleens and lymph nodes of 8–12-week-old mice. For some
experiments, negatively puriﬁed CD4þ T cells were further sorted on a FACS
AriaIII (BD Biosciences) to obtain naive CD44CD62LþCD4þ T cells using
anti-CD4-V450 (RM4-5, BD Biosciences), anti-CD44-PE (IM7, eBiosciences) and
anti-CD62L-Alexa Fluor 700 (MEL-14, BD Pharmingen) monoclonal antibodies
(mAbs) in a dilution of 1:500. Sorting purity was typically 497% in post-sort
analysis. The cells were primed with plate-bound anti-CD3 mAb (3 mgml 1,
145-2C11) and anti-CD28 mAb (5 mgml 1, 37.51, both mAbs produced and
puriﬁed ‘in house’) in the presence of recombinant human (rh) IL-2 (50U ml 1,
Novartis) and anti-mouse-IFN-g (5 mgml 1, XMG1.2, produced and puriﬁed
‘in house’). The cells were cultured under: neutral (Th0) conditions, by the addition
of anti-IL-4 (10% culture supernatant of clone 11B11), or Th9 conditions, by the
addition of rhTGFb (1.5 ng ml 1) and rmIL-4 (20 ngml 1). Some cultures were
supplemented with recombinant rat IFN-g (5 ng ml 1, Peprotech) as indicated
in the ﬁgure legends. Cells were usually harvested on day 2 for intracellular
staining and qRT-PCR analysis. For kinetic experiments, the cells were analysed
as indicated in ﬁgure legends.
For adoptive transfer experiments, CD4þ T cells were puriﬁed by negative
magnetic cell sorting (CD4þ T cell isolation kit, 130-104-454, Miltenyi) from the
spleens and lymph nodes of 8–12-week-old OTII and Irf1 /OTII transgenic
mice. The cells were differentiated under Th9 conditions in the presence of
anti-mIFNg (5mgml 1) and rat IFN-g (5 ngml 1). After 2 days, the cells were
harvested, washed, counted and 5 105 WT or Irf1 / OTII Th9 cells were
transferred by intraperitonal (i.p.) injection into Rag2 / mice.
Intracellular staining. For intracellular cytokine staining after differentiation, cells
were restimulated with phorbol myristate acetate (50 ngml 1) and ionomycin
(1 mgml 1) in the presence of brefeldin A (5 mgml 1, both from Sigma) for 4 h,
ﬁxed with formaldehyde (2%) and stained with anti-IL-9-allophycocyanin
(RM9A4, Biolegend) and anti-IFN-g-phycoerythrin (PE) (XMG 1.2, eBioscience)
mAbs. For intracellular staining of transcription factors after differentiation,
cells were ﬁxed with a Foxp3/Transcription Factor Fixation/Permeabilization
Concentrate and Dilutent (eBioscience) and then stained with: anti-Foxp3-PE
(FJK-16, eBioscience), anti-T-bet-PE (eBio4B10, eBioscience), anti-GATA-3-eF660
(TWAJ, eBioscience), anti-IRF4-AIFI647, (3E4, eBioscience) or anti-IRF1-PE
(D5E4, Cell Signaling) mAbs. All antibodies were used in a 1:500 dilution. The cells
were analysed by ﬂow cytometry using a FACSCalibur or a FACSAriaIII (BD,
Biosciences) with the DIVA software (BD, Biosciences) or the FlowJo Software
(Tree Star).
Phospho-ﬂow. For staining of phosphorylated STAT1, human Th9 cells were
harvested after 48 h of culture, rested for 4 h and treated with rhIFN-g
(100 ngml 1) for 20min. Then the cells were ﬁxed and permeabilized according to
BD Phosﬂow Protocol III using Lyse/Fix Buffer (557870, BD) and Perm Buffer III
(558050, BD) and stained with anti-human phospho-STAT1 (Y701)-eFluor660
(KIKSI0803, eBioscience, 1:100).
Stimulation and differentiation of human naive CD4þ T cells. PBMCs from
healthy donors were labelled with anti-CD4-Pac Blue (RPA-T4, BioLegend),
anti-CD45RA-FITC (HI100, eBioscience), anti-CD45RO-PE (UCHL1, BD) and
anti-CD25-allophycocyanin (BC96, eBioscience) in 1:500 dilutions, and then naive
CD4þ T cells (CD4þCD45RAþCD45ROCD25 ) were sorted using a FACS
AriaIII (BD), the purity was typically 497% in post-sort analysis. Naive CD4þ
T cells were cultured in RPMI complete media (5% human AB serum) with rhIL2
(30Uml 1) and activated with Dynabeads Human T-Activator CD3/CD28
(111.31D, Invitrogen, T cell/bead¼ 2:1). For induction of Th9 cell differentiation,
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rhIL-4 (30 ngml 1) and rhTGF-b1 (5 ngml 1) and either anti-hIFN-g
(5mgml 1) or rhIFN-g (50 ngml 1) were added to the cell cultures. Th0 cells
were differentiated in the presence of anti-hIL-4 and anti-hIFN-g (both
5 mgml 1). Cells were analysed by ﬂow cytometry for IRF1 and IRF4 presence
after 24–36 h of culture and for IL-9 and IFN-g production after 72 h of culture;
supernatants were collected after 72 h and IL-9 was measured by enzyme-linked
immunosorbent assay (ELISA; human IL-9 ELISA Max, 434705, BioLegend).
RNA-mediated interference. An Amaxa Human T cell Nucleofector Kit (VPA
1002, Lonza) was used for knockdown of human IRF1 by siRNA in naive CD4þ T
cells according to the manufacturer’s instructions. Naive CD4þ T cells (5 106)
were activated with Dynabeads Human T-Activator CD3/CD28 overnight and then
transduced with 3 mM IRF1-speciﬁc siRNA (ONTARGETplus, L011704-00) or
control scrambled RNA (both Dharmacon) by the T-23 transfection program
(Amaxa). Thereafter, the cells were cultured under Th9 conditions for additional
24–48 h, followed by ﬂow cytometric analysis and evaluation of IL9 mRNA by
qRT-PCR and IL-9 production by ELISA.
Immunoblot analysis. Puriﬁed murine CD4þ T cells were left unstimulated or
stimulated as indicated in the ﬁgure legends. For detection of Tyr694STAT5 and
Tyr641STAT6 phosphorylation, cells were preactivated under Th9 conditions in the
presence of anti-mIFNg (5mgml 1) and rIFN-g (5 ng ml 1) for 2 days, then
washed and rested in cytokine-free medium for 8 h. Preactivated cells were treated
with rat IFN-g (5 ngml 1) in combination with either rmIL-4 (20 ngml 1) or
rhIL-2 (50Uml 1) for 20 or 60min. Whole-cell lysates were prepared as described
previously47, 20mg of total protein were loaded per lane and proteins were detected
according to standard protocols. The following Abs were used: anti-b-actin
(AC-15, Sigma-Aldrich), anti-IRF-1 (M-20, Santa Cruz), anti-IRF-4 (M-17,
Santa Cruz), anti-STAT1 (#9172, Cell Signaling) anti-P-STAT1 (Tyr701, D4A7,
Cell Signaling), anti-STAT5 (C-17, Santa Cruz), anti-P-STAT5 (Tyr694, C11C5,
Cell Signaling), anti-STAT6 (M-20, Santa Cruz), anti-P-STAT6 (Tyr641, sc11762,
Santa Cruz), anti-goat IgG-HRP (#sc-2020, Santa Cruz), anti-rabbit IgG-HRP
(#sc-2004, Santa Cruz), and anti-mouse IgG-HRP (#sc-2055, Santa Cruz).
Chromatin immunoprecipitation. Th9 cells cultured for 2 days in the presence of
anti-mIFNg (5 mgml 1) and/or rat IFN-g (5 ngml 1) as indicated in the ﬁgure
legends. In all, 2–5 106 cells were crosslinked with 1% formaldehyde for 6min at
room temperature. Subsequently, ChIP was performed as previously described48.
Lysed cells were sonicated in a Bioruptor Plus (Diagenode) with 30 s ON, 30 s OFF
on high power output for 27–33 cycles at 4 C. For immunoprecipitation, 2.5–4 mg
of the following Abs were used: anti-IRF1 (M-20, sc-640x, Santa Cruz), anti-STAT1
(#9172, Cell Signaling), anti-RNA pol II (N-20, sc-899x, Santa Cruz), anti-H4-Ac
(06-866, Millipore) and control IgG (#2729, Cell Signaling). qRT-PCR with the
precipitated chromatin was performed to calculate the percentage of input. Primer
sequences are provided in Supplementary Table 1. All ampliﬁcations were
performed in triplicate with the QuantiTect SYBR Green PCR Kit (204143,
Qiagen). Control ChIP was performed with a respective control antibody to ensure
speciﬁcity. Values for nonspeciﬁc binding (as determined by control IgG) were
subtracted. After normalization of the data according to the control, the speciﬁc
pulldown (input %) was calculated.
qRT-PCR. Total RNA was extracted from cells at day 1 or 2 of culture. For RNA
isolation, the High Pure RNA Isolation Kit (11828665001, Roche) was used.
Complementary DNA (cDNA) was synthesized with oligo(dT) primers using the
RevertAid First Strand cDNA Synthesis Kit (K1621, Thermo Scientiﬁc) and gene
expression was examined with an ABI Prism 7500 Sequence Detection System
(Applied Biosystems) using the SYBR green I qPCR Core Kit (10-SN10-05NR,
Eurogentec). Levels of each gene were normalized to hypoxanthine-guanine
phosphoribosyl transferase (Hprt1) expression using the DDCt method, with the
lowest experimental value set to 1. The primer sets are provided in Supplementary
Table 1.
Luciferase reporter assay. Naive CD62LþCD4þ T cells from C57Bl/6 mice were
isolated and stimulated for 2 days under Th0 conditions. The preactivated Th0 cells
were transfected with the Mouse T Cell Transfection Kit (Amaxa) according to the
manufacturer’s instructions with 0.5 mg of reporter vector coding for the Fireﬂy
Luciferase (pGL3 basic, Promega) under the control of the Il9 promoter (CNS1)
( 610 to þ 32)11 or mutants within Il9 promoter-IRF-III (M1 or M3).
Additionally, cells were transfected with 2 mg of the IRF411 in pcDNA 3.1(þ )
(Invitrogen) vector and/or with 2 mg of the IRF1 or IRF1DDBD, all in pmax
(Lonza) vectors and/or with 2 mg of respective control vectors. To control
transfection efﬁciency and absolute cell numbers, cells were co-transfected with
0.5 mg of the pRSV b-gal plasmid. In experiments with IRF4- and IRF1-expressing
vectors, Th0 cells were transfected with the total amount of 5 mg DNA.
Twenty-four hours after transfection, cells were stimulated with phorbol myristate
acetate (20 ngml 1) and ionomycin (370 ngml 1) for further 24 h. Harvested
cells were washed and lysed and the luciferase activity was measured for each
sample and divided by the b-galactosidase activity of the sample to obtain relative
luciferase activity (relative light units).
For the generation of the IRF1 vector, the gene encoding murine full-length
IRF1 (accession number NM_008390) was ampliﬁed by PCR with the following
primers: forward: 50-ATG CCA ATC ACT CGA ATG-30 ; and reverse 50-CAG
AGA CCC AAA CTA TGG TG-30 . Mutated IRF1 lacking the DNA-binding
domain (IRF1DDBD) was ampliﬁed with the following primers: forward: 50-ATG
CTC ACC AGG AAC CAG AGG-30 , and reverse 50-CAG AGA CCC AAA CTA
TGG TG-30 . The PCR products were control digested with SalI and Kpn1 and
cloned into the vector pmax (Lonza). Constructs were sequenced to prove
authenticity.
Mutations in potential IRF-binding sites within the Il9 CNS1-IRF-III site
were generated using the QuickChange Site-Directed Mutagenesis Kit (Agilent
Laboratories) and the following primers: M1.for: 50-CTG AAA TAC TAA AGG
AGG AGT TAA AGA TCT AGC CCC AAC CCC CTT-30 , M1.rev: 50-AAG GGG
GTT GGG GCT AGA TCT TTA ACT CCT CCT TTA GTA TTT CAG-30 , M3.for:
50-CTT CAA ATA GTC GGG TTC TGA GGT ACT AAA GGA AAA GTT AAA
GAT CTA GCC C-30, and M3.rev: 50-GGG CTA GAT CTT TAA CTT TTC CTT
TAG TAC CTC AGA ACC CGA CTA TTT GAA G-30 . Constructs were veriﬁed by
DNA sequencing.
Retroviral transduction. The gene encoding murine full-length IRF1 (accession
number NM_008390) was ampliﬁed by PCR with the following primers: forward:
50-CCA TGC CAA TCA CTC GAA TG-30 ; and reverse 50-CAG AGA CCC AAA
CTA TGG TG-30 . The PCR product was control digested with BglII and EcoRI and
cloned into the retroviral vector pMSCV containing the IRES-regulated gene for
GFP or Thy.1. The construct was sequenced to prove authenticity. The retroviral
vector pMSCV containing IRF4-IRES-GFP, the empty control vector containing
IRES-GFP and transduction were described previously64 WT, Irf4 / or Irf1 /
CD4þ T cells were primed under Th0 conditions and, on day þ 1, were infected
with an IRF1-expressing retrovirus (IRF1-RV), IRF1 mutant-expressing retrovirus
(IRF1DDBD-RV), IRF4-expressing retrovirus (IRF4-RV) or a control retrovirus
(Control-RV). Transfected cells were cultured under Th9 conditions (TGF-b and
IL-4) for 48 h, then washed and rested in media containing rhIL-2 (50U) and
amIFN-g for 72 h. Thereafter, the cells were re-cultured under Th9 conditions for
additional 48 h, then washed, restimulated and analysed by ﬂow cytometry for
intracellular IL-9, or without restimulation, the cells were analysed for intracellular
IRF1 and IRF4 levels.
Asthma adoptive transfer model. Rag2 / mice received 5 105 WT or
Irf1 / OTII-Th9 cells on day 0 by i.p. injection. Mice were then challenged via
the airways with nebulized OVA (1% in saline) with an ultrasonic nebulizer
(NE-U17; Omron, Hoofdrop, The Netherlands) for 20min daily from day 1 to day
6. To neutralize IL-9 cytokine in vivo, mice were injected i.p. either with 30 mg
anti-IL-9 (MM9C1, produced and puriﬁed ‘in house’) or rat IgG (Sigma) antibody
on days þ 1, þ 3 and þ 5. On day 7, BAL and lung tissue were collected.
BAL and lung single-cell preparation. Cells were isolated by lavage of the lungs
via a tracheal tube with PBS (1ml). Numbers of BAL cells were counted with
trypan blue dye exclusion. Differential cell counts were made from cytocentrifuged
preparations, ﬁxed and stained with the Microscopy hemacolor set (Merck,
Darmstadt, Germany). The percentage and absolute numbers of each cell type
were calculated.
Lungs were ﬁxed by inﬂation (1ml) and immersion in 10% formalin and
embedded in parafﬁn. Tissue sections were stained with haematoxylin and eosin
and periodic acid-Schiff. Slides were examined in a blinded manner by two
experienced observers by microscopy (BX40, Olympus, Germany) and
peribronchial and perivascular inﬂammation was graded by a semiquantitative
score (no inﬂammation¼ 0, severe inﬂammation¼ 10). For each slide, ﬁve
randomly chosen areas were scored. As for periodic acid-Schiff-stained slides,
the number of goblet cells was analysed by the imaging software (Analysis, Soft
Imaging Systems, Stuttgart, Germany). The number of mucus-containing cells per
millimetre of basement membrane was determined.
Lungs were minced and enzymatically digested for 1 h with collagenase D
(1mgml 1) and DNase I (20 mg ml 1, both from Roche) in RPMI medium.
Dispersed cells were passed through a 30-mm cell strainer (Miltenyi Biotec).
Isolated lung cells (4 105 in 200ml) were stimulated with 2mM OVA323–339 for
72 h, and the supernatants were analysed for the amounts of IL-9, IFN-g and IL-13
by ELISA (IL-13 and IFN-g, from BD Pharmigen, for murine IL-9 detection, mAbs
229.4 and C12 were used, produced and puriﬁed ‘in house’).
RNA-Seq and bioinformatical analysis. Naive CD4þ T cells isolated from WT
and Irf1 / mice were cultured for 2 days under Th9 conditions in the presence
of IFN-g (5 ng ml 1). RNA was puriﬁed with the RNeasy Plus Mini Kit according
to the manufacturer’s protocol (Qiagen). RNA was quantiﬁed with a Qubit 2.0
ﬂuorometer (Invitrogen) and the quality was assessed on a Bioanalyzer 2100
(Agilent) using a RNA 6000 Nano chip (Agilent). Samples with an RNA integrity
number of 48 were used for library preparation. Barcoded mRNA-seq cDNA
libraries were prepared from 400 ng of total RNA using NEBNext Poly(A) mRNA
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Magnetic Isolation Module and NEBNext Ultra RNA Library Prep Kit for Illumina
according to the manual. Quantity was assessed using Invitrogen’s Qubit HS Assay
Kit and library size was determined using Agilent’s 2100 Bioanalyzer HS DNA
assay. Barcoded RNA-Seq libraries were onboard clustered using HiSeq Rapid SR
Cluster Kit v2 using 8 pM and 50 bps were sequenced on the Illumina HiSeq2500
using the HiSeq Rapid SBS Kit v2 (50 Cycle). The raw output data of the HiSeq was
preprocessed according to the Illumina standard protocol. Quality control on the
sequencing data was performed with the FastQC tool (available at http://www.
bioinformatics.babraham.ac.uk/projects/fastqc/), as well as the comprehensive
Qorts suite65. Inspecting the produced reports, all samples were deemed of good
quality for further processing. Short reads alignment was performed with the
ENSEMBL Mus_musculus.GRCm38 chosen as the reference genome. The
corresponding annotation (ENSEMBL v76) was also retrieved from the ENSEMBL
FTP website (http://www.ensembl.org/info/data/ftp/index.html). The STAR aligner
(version 2.4.0b) was used to perform mapping to the reference genome. Alignments
were processed with the featureCounts66 function of the Rsubread package, using
the annotation ﬁle, also used for supporting the alignment. Exploratory data
analysis was performed with the pcaExplorer package. Differential expression
analysis was performed with DESeq2 (version 1.12.3, https://www.ncbi.nlm.nih.
gov/pubmed/25516281), setting the False Discovery Rate to 0.05 (ref. 67). Gene
expression proﬁles were plotted as heatmaps (colour-coded z-scores for each
fragments per kilobase of exon per million fragments mapped value) with the R
statistical software. GSEA was performed as previously described68.
ChIP-Seq and bioinformatics analysis. Naive CD4þ T cells were cultured under
Th9 conditions for 2 days, then rested for 3 days and restimulated under Th9
conditions with or without IFN-g treatment for additional 2 days. ChIP-Seq
was performed as previously described47. Shortly, for IRF1 and IRF4 ChIP-seq,
107 cells were crosslinked with 1% paraformaldehyde for 30min, and for H3K27ac
ChIP-seq, 3 105 cells were crosslinked with 1% paraformaldehyde for 5min.
Subsequently, cells were lysed and sonicated using Digital Soniﬁer (Branson).
For immunoprecipitation, the lysate was incubated overnight with 50 ml DynaBeads
IgG magnetic beads (Thermo Fisher) that had been preincubated with 2.5 mg of the
following antibodies: anti-IRF1 (abcam, ab186384), anti-IRF1 (M-20, sc-640x,
Santa Cruz), anti-IRF4 (abcam, ab101168), and anti-H3K27ac (GeneTex,
GEX60815). After washing, elution and reverse crosslinking at 65 C overnight,
precipitated DNA was puriﬁed using the MinElute PCR Puriﬁcation Kit (Qiagen).
For IRF1 and IRF4 CHIP-seq, puriﬁed DNA was fragmented using Covaris
Focused-ultrasonicator S220 (Covaris) before library preparation. Library was
constructed using the KAPA Library Preparation Kit Ion Torrent (KAPA
Biosystems) according to the manufacturer’s instructions and sequenced using Ion
S5 (Thermo Fisher). Quality control on the raw data was performed with FastQC.
Mapping was performed against the Mus Musculus GRCm38 reference with
bowtie2, version 2.2.9. The aligned ﬁles were converted to bam, sorted and indexed
for the subsequent steps. Additional controls to check antibody enrichment was
done with the NGSplot tool and inspecting the metagene proﬁles combined with
basic mapping statistics. Peak calling was performed with MACS2, using the sharp
peak calling algorithm. Downstream analyses were performed with the
ChIPpeakAnno package. Promoter regions were deﬁned as the genomic intervals
spanning 500 bp upstream and 500 bp downstream annotated Transcription Start
Sites (retrieved from the ENSEMBL annotation). Occupancy levels were quantiﬁed
with the summarizeOverlaps function of the GenomicAlignments package, and
values were subsequently normalized and log2 transformed (after adding1 as
pseudocount). Functional annotation of the affected promoters was performed
with topGO. Enriched GO Terms in the genes annotated to Irf1 peaks was
performed with the topGO Bioconductor package, using the elim algorithm. Motif
analysis was performed with the Biostrings package, and their occurrencies are
presented with the functions in the UpSetR package (EICE: GGANTGA, AICE:
TGAG/CTCA, ISRE AANNGAAA). The MEME/DREME software tool69 to search
for over-represented motifs was used.
Statistical analysis. For statistical analysis, a two-tailed Student’s t-test was
performed using the GraphPad Prism software (GraphPad Software). For analysis
of data obtained in the allergic airway adoptive transfer model, differences between
groups were evaluated by one-way ANOVA test with Tukey’s post-test. P values are
indicated as follows: *Po0.05; **Po0.005; ***Po0.001.
Data availability. Sequence data that support the ﬁndings of this study have been
deposited in GEO with the primary accession codes GSE96818 and GSE96699. The
authors declare that all other data supporting the ﬁndings of this study are available
within the article and its Supplementary Information ﬁles.
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